Lying down for long periods raises Alzheimer's disease risk
Lying down for lengthy periods increases the risk of Alzheimer's disease, regardless of how much exercise a person does.
Health experts have long recommended doing plenty of exercise to combat the health risks of sedentary jobs but a new study has revealed that it might not make a difference in the battle against the brain illness.
Research conducted at the Vanderbilt University Medical Center in the US city of Nashville tracked over 400 dementia-free adults aged over 50 and asked them to wear a watch measuring their activity levels for a week.
It was revealed that those with more sedentary time were more likely to experience Alzheimer's symptoms, irrespective of how much they exercised.
Professor Angela Jefferson, an author of the study, said: "This research highlights the importance of reducing sitting time, particularly among ageing adults at increased genetic risk for Alzheimer's disease.
"It is critical to our brain health to take breaks from sitting throughout the day and move around to increase our active time."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
SBS Australia
27-05-2025
- SBS Australia
Australia approves new drug to slow Alzheimer's progression
This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer's affected brain, with abnormal levels of the beta-amyloid protein clumping together to form plaques, brown, that collect between neurons and disrupt cell function. Credit: AP
The Age
25-05-2025
- The Age
Brain scan to detect Alzheimer's before symptoms appear is world first
It has already been designated by the US Food and Drug Administration for use in the United States as a 'breakthrough' device. The neuroscientist behind the advances said it meant medical professionals were able to see changes in the brain far earlier, at a level normally only be possible via a post-mortem examination. Over the past year, two major treatments for Alzheimer's disease have been given the green light by UK regulators. Donanemab and lecanemab are the first treatments found to slow progression of the disease. Donanemab has just been approved for use in Australia, however is not yet available on the Pharmaceutical Benefits Scheme. Lecanemab has not received approval. Both have also been blocked for use on Britain's National Health Service, on the grounds they are not cost-effective. Experts believe that diagnosing dementia early is key to making treatments more effective and helping to ensure they become more widely available. Almost 1 million people in Britain are living with dementia, but this number is expected to reach 1.4 million by 2040. About 400,000 people have dementia in Australia. Oxford Brain Diagnostics, a spinout company from the University of Oxford, was founded by Dr Steven Chance, former associate professor of neuroscience at Oxford, and Professor Mark Jenkinson, a leading expert in brain imaging. Loading The breakthrough was achieved after the company received funding from British investment firm BGF and the Oxford Technology & Innovations Fund. Identify other neurodegenerative conditions Studies have found the method can detect neurodegenerative changes before any visible brain shrinkage or atrophy appears on standard imaging as well as distinguish between different types of dementia. It has also been found to predict which individuals with mild cognitive impairment are more likely to develop dementia. The platform could also help to identify other neurodegenerative conditions including Parkinson's disease and multiple sclerosis. Chance said: 'The core technology is founded on my background, looking at the microscopic structure of brains at autopsy for many years. You couldn't do that with a living patient and this is what we needed.' He said the technology could have a transformative impact, bringing hope to 'millions of people who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health'. For now, the target patient market is those suffering mild cognitive decline, allowing professionals to differentiate between types of dementia and other neurodegenerative diseases. Chance said clinics might offer annual checks for those with concerns about memory problems. In time, and with the advent of more medicines to treat dementia, such advances could be rolled out to those in mid-life, he said. 'More than 20 per cent of those over 50 have Alzheimer's-type changes, small-scale changes that would be otherwise invisible. These breakthroughs open up a whole new way of monitoring brain health.' Alzheimer's Research UK policy head David Thomas said: 'Dementia is caused by diseases that often begin years before symptoms appear, and so finding new ways to detect these diseases earlier is vital. There is a huge amount of progress happening in this space and it's encouraging to see UK companies contributing to that. 'While this technology shows promise for diagnosing dementia earlier, so far it has only been validated in research settings. We're still some way off it being used within the NHS and we would need to see much more real-world clinical data to fully understand its potential. Loading 'Improving early and accurate diagnosis is crucial – not only to give people clarity about their condition but also to ensure they can access the right support and, in future, new treatments as they become available.' The Telegraph, London
Sydney Morning Herald
25-05-2025
- Sydney Morning Herald
Brain scan to detect Alzheimer's before symptoms appear is world first
It has already been designated by the US Food and Drug Administration for use in the United States as a 'breakthrough' device. The neuroscientist behind the advances said it meant medical professionals were able to see changes in the brain far earlier, at a level normally only be possible via a post-mortem examination. Over the past year, two major treatments for Alzheimer's disease have been given the green light by UK regulators. Donanemab and lecanemab are the first treatments found to slow progression of the disease. Donanemab has just been approved for use in Australia, however is not yet available on the Pharmaceutical Benefits Scheme. Lecanemab has not received approval. Both have also been blocked for use on Britain's National Health Service, on the grounds they are not cost-effective. Experts believe that diagnosing dementia early is key to making treatments more effective and helping to ensure they become more widely available. Almost 1 million people in Britain are living with dementia, but this number is expected to reach 1.4 million by 2040. About 400,000 people have dementia in Australia. Oxford Brain Diagnostics, a spinout company from the University of Oxford, was founded by Dr Steven Chance, former associate professor of neuroscience at Oxford, and Professor Mark Jenkinson, a leading expert in brain imaging. Loading The breakthrough was achieved after the company received funding from British investment firm BGF and the Oxford Technology & Innovations Fund. Identify other neurodegenerative conditions Studies have found the method can detect neurodegenerative changes before any visible brain shrinkage or atrophy appears on standard imaging as well as distinguish between different types of dementia. It has also been found to predict which individuals with mild cognitive impairment are more likely to develop dementia. The platform could also help to identify other neurodegenerative conditions including Parkinson's disease and multiple sclerosis. Chance said: 'The core technology is founded on my background, looking at the microscopic structure of brains at autopsy for many years. You couldn't do that with a living patient and this is what we needed.' He said the technology could have a transformative impact, bringing hope to 'millions of people who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health'. For now, the target patient market is those suffering mild cognitive decline, allowing professionals to differentiate between types of dementia and other neurodegenerative diseases. Chance said clinics might offer annual checks for those with concerns about memory problems. In time, and with the advent of more medicines to treat dementia, such advances could be rolled out to those in mid-life, he said. 'More than 20 per cent of those over 50 have Alzheimer's-type changes, small-scale changes that would be otherwise invisible. These breakthroughs open up a whole new way of monitoring brain health.' Alzheimer's Research UK policy head David Thomas said: 'Dementia is caused by diseases that often begin years before symptoms appear, and so finding new ways to detect these diseases earlier is vital. There is a huge amount of progress happening in this space and it's encouraging to see UK companies contributing to that. 'While this technology shows promise for diagnosing dementia earlier, so far it has only been validated in research settings. We're still some way off it being used within the NHS and we would need to see much more real-world clinical data to fully understand its potential. Loading 'Improving early and accurate diagnosis is crucial – not only to give people clarity about their condition but also to ensure they can access the right support and, in future, new treatments as they become available.' The Telegraph, London
